HLA-A2-restricted peptide epitopes of CD105 (endoglin) for cancer vaccination
The following invention is a new, peptide based vaccination against genetical stable tumor stroma-associated antigens. Because of significant upregulation of certain proteins (e.g. FAPα, CD105) tumor stroma cells are suitable targets for anti-tumor therapy. This technology employs these specific antigens in the vaccine design to avoid an immunologic attack on normal unaltered cells.
Further Information: PDF
Bayerische Patentallianz GmbH
Phone: +49 89 5480177-0
Contact
Peer Biskup
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Zap Energy achieves 37-million-degree temperatures in a compact device
New publication reports record electron temperatures for a small-scale, sheared-flow-stabilized Z-pinch fusion device. In the nine decades since humans first produced fusion reactions, only a few fusion technologies have demonstrated…
Innovative microscopy demystifies metabolism of Alzheimer’s
Researchers at UC San Diego have deployed state-of-the art imaging techniques to discover the metabolism driving Alzheimer’s disease; results suggest new treatment strategies. Alzheimer’s disease causes significant problems with memory,…
A cause of immunodeficiency identified
After stroke and heart attack: Every year, between 250,000 and 300,000 people in Germany suffer from a stroke or heart attack. These patients suffer immune disturbances and are very frequently…
